LIMN Liminatus Pharma, Inc.

Nasdaq liminatuspharma.com


$ 1.05 $ -0.07 (-6.25 %)    

Thursday, 20-Nov-2025 15:59:53 EST
QQQ $ 584.62 $ -14.20 (-2.37 %)
DIA $ 458.30 $ -3.66 (-0.79 %)
SPY $ 652.19 $ -10.10 (-1.52 %)
TLT $ 89.30 $ 0.35 (0.39 %)
GLD $ 375.00 $ -0.11 (-0.03 %)
$ 1.05
$ 1.13
$ 1.04 x 644
$ 1.07 x 84
$ 1.04 - $ 1.12
$ 1.02 - $ 33.66
124,561
na
28.36M
$ -1.11
nm
TBD
na
na ($ 0.00)
na
TBD na
How to Read 10-K & 10-Q Reports To View SEC Filing Reports, Please Register or Sign In
# Filing Date Period End Date Type Report Link
1 11-14-2025 09-30-2025 10-Q
2 10-04-2025 06-30-2025 10-Q
3 05-31-2025 03-31-2025 10-Q
Guide for Analyst Ratings To View Analyst Ratings, Please Register or Sign In
# Date Analyst Firm Upside/Downside Price Target Change Rating Change Current Rating

News

OPINIONS

Core News & Articles

Liminatus Pharma, Inc. (NASDAQ:LIMN), La Palma, CA, a clinical-stage immuno-oncology company developing next-generation CD47-bl...

Core News & Articles

Liminatus Pharma, Inc. (NASDAQ:LIMN), a preclinical-stage biopharmaceutical company dedicated to the development of targeted ca...

Core News & Articles

Liminatus Pharma, Inc. (NASDAQ:LIMN), a preclinical-stage biopharmaceutical company dedicated to the development of targeted ca...

Core News & Articles

Liminatus Pharma, Inc. (NASDAQ:LIMN), a preclinical-stage biopharmaceutical company dedicated to the development of targeted ca...

Core News & Articles

Liminatus Pharma, Inc. has entered into a Memorandum of Understanding (MOU) to form a research and development consortium with ...

CLASS ACTION DEADLINES - JOIN NOW!

NEW CASE INVESTIGATION